Neurocrine Biosciences (NBIX) Shares Outstanding (Diluted Average) (2010 - 2026)

Neurocrine Biosciences has reported Shares Outstanding (Diluted Average) for 17 years, with the latest figure at $103.4 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 0.88% year-over-year to $103.4 million; the trailing twelve-month figure through Mar 2026 stood at $103.4 million (up 0.88% YoY), and the FY2025 full-year result was $102.5 million, down 1.16% from the prior year.
• Shares Outstanding (Diluted Average) for Q1 2026 stood at $103.4 million, up from $102.5 million in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $104.3 million in Q3 2024, with the low at $95.6 million in Q2 2022.
• Historically, Shares Outstanding (Diluted Average) has averaged $101.0 million across 5 years, with a median of $101.0 million in 2023.
• Annual changes were most pronounced in 2024 — Shares Outstanding (Diluted Average) advanced 6.69% — and 2025, when it dropped 2.79%.
• Neurocrine Biosciences' Shares Outstanding (Diluted Average) stood at $98.9 million in 2022, then rose by 2.12% to $101.0 million in 2023, then increased by 2.67% to $103.7 million in 2024, then declined by 1.16% to $102.5 million in 2025, then increased by 0.88% to $103.4 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $103.4 million (Q1 2026), $102.5 million (Q4 2025), and $102.0 million (Q3 2025), per Business Quant data.